A set of guidelines have been developed that can help predict the risk of bacterial meningitis for children with cerebrospinal fluid pleocytosis (presence of greater number of white blood cells than normal), reducing unnecessary hospitalizations and antibiotics, according to a study in the January 3 issue of JAMA.

Although bacterial meningitis is the greatest concern when evaluating and treating children with cerebrospinal fluid (CSF) pleocytosis, the majority of these children have viral rather than bacterial meningitis, according to background information in the article. However, because exclusion of bacterial meningitis requires negative CSF (and blood) cultures after 2 to 3 days of incubation, most children with CSF pleocytosis are admitted to the hospital to receive broad-spectrum antibiotics while awaiting culture test results. A highly accurate decision support tool that could identify which children with CSF pleocytosis had a near-zero risk of bacterial meningitis by using clinical and laboratory measures readily available at the time the child is in the clinic could guide decision making and limit unnecessary hospital admissions and prolonged antibiotic use.

Lise E. Nigrovic, M.D., M.P.H., of Children’s Hospital Boston and Harvard Medical School, and colleagues conducted a study to validate in a large population the clinical prediction rule, the Bacterial Meningitis Score, which classifies patients at very low risk of bacterial meningitis if they lack 5 criteria, which include certain CSF measurements and a history of seizure. The multicenter study was conducted in the emergency departments of 20 U.S. academic medical centers between January 2001 and June 2004 and included 3,295 children, age 29 days to 19 years with CSF pleocytosis.

Among these patients, 121 (3.7 percent) had bacterial meningitis and 3,174 (96.3 percent) had aseptic (nonbacterial) meningitis. Of the 1,714 patients categorized as very low risk by the Bacterial Meningitis Score, only 2 had bacterial meningitis (both were younger than 2 months old) and 1,712 had aseptic meningitis. The sensitivity of the Bacterial Meningitis Score (i.e., having 1 or more Bacterial Meningitis Score risk factor) for bacterial meningitis was 98.3 percent and the specificity was 61.5 percent.

The authors write that for patients with at least 1 Bacterial Meningitis Score risk factor or who are younger than 2 months, they suggest admission to the hospital and administration of parenteral (administered intravenously or by injection) antibiotics.

“In the conjugate H influenzae type b and pneumococcal vaccines era, bacterial meningitis has become an uncommon disease in U.S. children. Therefore, the majority of children with CSF pleocytosis have aseptic rather than bacterial meningitis. Furthermore, our study confirms that most children with CSF pleocytosis are admitted to the hospital to receive parenteral antibiotics while awaiting bacterial culture test results. Using the Bacterial Meningitis Score prediction rule to assist with clinical decision making could substantially reduce unnecessary hospital admissions for children with CSF pleocytosis at very low risk of bacterial meningitis. Future investigations should study the clinical implementation of the Bacterial Meningitis Score as a guide to help care for children with CSF pleocytosis,” the researchers conclude.

American Medical Association (AMA)
515 N. State St.
Chicago, IL 60610
United States
ama-assn/

University of Manchester scientists have shown that a protein involved in blood clotting can be used to diagnose and subsequently monitor the treatment of a group of childhood genetic diseases.

In the study, published in the Journal of Inherited Metabolic Disease, the researchers were able to show that the clotting agent, heparan cofactor II/Thrombin (HCII/T) complex, could be used as a ‘biomarker’, or biological tell, in individuals with mucopolysaccharide (MPS) diseases.

MPS diseases are severe metabolic conditions caused by a genetic defect that affects the body’s ability to break down complex sugars in cells and the bloodstream. The conditions result in a range of symptoms from abnormal skeletal development to mental decline and even premature death depending on the type of sugars built up in the body.

Treatment options have been limited but recent advances whereby the missing or faulty enzyme that breaks down the sugars is replaced artificially in affected individuals has made the need for an accurate diagnostic tool for these diseases more pressing.

Lead researcher Dr Brian Bigger, from Manchester’s MPS Stem Cell Research Laboratory, said: “HCII/T complex was originally developed in Canada as a test for patients with MPSI, II and VI. We were able to show that HCII/T complex can clearly distinguish between untreated patients with MPSI, MPSII, MPSIIIA, MPSIIIB, MPSIIIC, MPSVI and unaffected individuals.

“We also went on to monitor long-term clinical outcomes in patients with MPSI, MPSII and MPSVI after treatment to show that elevations of both this biomarker, and the dermatan sulphate:chondroitin sulphate biomarker currently used in the diagnostic laboratory in Manchester, correlated with clinical treatment outcomes in patients.

“Two of the sugars that are commonly accumulated in MPS diseases are heparan sulphate (HS) and dermatan sulphate (DS). Other sugars such as chondroitin sulphate (CS) are usually not accumulated in the disease. By measuring the ratio of DS:CS in urine we can accurately diagnose the disease, but detection of sugars is expensive and technically challenging. Instead, the HCIIT method relies on detection of proteins binding to sugars and is much cheaper to perform.”

Simon Jones, a consultant paediatrician at St Mary’s Hospital in Manchester and co-author on the paper, added: “These are difficult diseases to treat and monitor so advances such as this will help us to diagnose and treat patients more effectively in the future.”

Notes:

The open-access paper: “Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short and long-term treatment effects in mucopolysaccharide diseases”

Source:
Aeron Haworth

University of Manchester

A long term study found
that a type of stem cell transplant used for patients with life threatening
diseases, such as leukemia and lymphoma, results in decreased sexual
function and activity for recipients. Further, males are likely to recover
from these changes over time, while the sexuality of female patients
remains compromised. In addition, neither male nor female long-term cancer
survivors regained levels of sexual activity and function equal to those of
their peers who have not had cancer, according to a Blood First Edition
Paper prepublished online today. Blood is the official journal of the
American Society of Hematology.

“Survival without a sex life should not be what cancer survivors settle
for or what health-care professionals consider a successful outcome of
cancer treatment,” stated lead study author, Karen Syrjala, PhD,
co-director of the Survivorship Program at the Fred Hutchinson Cancer
Research Center. “Sexual dysfunction in survivors of cancer needs to become
a priority for research funding and a routine topic of discussion between
doctors and their patients after cancer treatment.”

In an allogeneic hematopoeitic stem cell transplantation, patients with
diseases of the blood, bone marrow, or certain types of cancers receive an
infusion of new stem cells from a sibling or tissue-matched unrelated donor
to replace the damaged or destroyed cells in their bone marrow needed for
the production of blood cells. Before the transplant, high-dose
chemotherapy is administered to kill residual cancer cells and to suppress
the immune system so that the patient’s body will not reject the new
tissue.

The results of questionnaires on sexual function were reported for 161
patients scheduled to receive this procedure at the Fred Hutchinson Cancer
Research Center in Seattle. The patients ranged in age from 22-64 years
with an average age of 41 and a nearly even split by gender.

Before the transplant, study participants completed an assessment of
their sexual health at the clinic, and, after the procedure, surveys were
mailed to the patients to complete at the six-month interval and after one,
two, three, and five years. The response rate to the questionnaire averaged
84 percent with all participants completing one or more surveys during the
five-year period.

The surveys included 37 questions in the areas of interest, desire,
arousal, orgasm, satisfaction, activity, relationship, masturbation, and
sexual problems. The male and female versions had the same content except
for variations in the problems section according to sex. In addition, those
who were not sexually active were provided with a list of possible reasons
and asked to mark as many as applied.

At five years, the assessments were compared against a control group
consisting of siblings or friends of the study patients that were within
five years of the participant’s age and who were of the same gender,
ethnicity, race, and educational background. If a local match was not
available, the researchers recruited volunteers from the community that fit
the criteria.

At the six-month mark, both genders had decreased sexual activity, but,
by one year, sexual activity for the majority of the men (74 percent) had
recovered to the levels seen at the beginning of the study. For women,
recovery of sexual activity took longer, with just over half (55 percent)
returning to sexual activity after two years. Though sexual activity was
restored for these patients, for those who were sexually active at the
five- year mark, 46 percent of the men and 80 percent of the women reported
problems that disrupted sexual function.

According to the researchers, sexual dysfunction in transplant patients
is likely caused by systemic therapies, such as total body irradiation and
chemotherapy drugs known as alkylating agents, which are known to
permanently damage endocrine glands that play a critical role in the
development and regulation of the reproductive system.

In addition, chronic graft-versus-host disease (GVHD), a common
complication of transplantation experienced by 65 percent of the patients
in this study, may cause shrinkage of the vaginal tissues and changes to
the vaginal lining that can contribute to sexual dysfunction in women. For
males, testosterone levels and the cavernosal arteries of the penis are
affected, eroding libido and erectile function.

Lack of interest or libido explained sexual inactivity in part for
nearly 20 percent of female survivors at both six months and five years,
suggesting that this problem did not improve over time. In contrast, for
males, lack of interest or libido as a reason for inactivity declined from
14 percent to 6 percent between six months and five years.

At the five-year mark, the rates of sexual activity and sexual function
for both male and female patients were below those of the control group,
suggesting that they did not fully recover from the effects of the cancer
itself or cancer treatments. Further studies are needed to determine if
hormone treatments for both sexes or other therapies will help these
patients achieve the same sexual function and activity as their peers.

The researchers also recommend that patients undergoing stem cell
transplantation be made aware of potential changes in their sexuality and
given resources to address these needs to help improve long-term quality of
life. Men may benefit from reassurance that erectile function and sexual
desire should improve by one to two years after treatment, but that methods
such as testosterone replacement, erectile-function medications, and other
adaptive strategies can be considered if problems continue. For women,
methods that focus on communication with their partners about changes in
sensation, strategies for enhancing libido, and use of vaginal lubricants,
dilators, or vibrators to assist with adapting to genital changes may help
to maintain sexual responsiveness.

This work was supported by grants from the National Cancer Institute.

The American Society of Hematology (hematology) is the
world’s largest professional society concerned with the causes and
treatment of blood disorders. Its mission is to further the understanding,
diagnosis, treatment, and prevention of disorders affecting blood, bone
marrow, and the immunologic, hemostatic, and vascular systems, by promoting
research, clinical care, education, training, and advocacy in hematology.

Blood, the official journal of the American Society of Hematology, is
the most cited peer-reviewed publication in the field. Blood is issued to
Society members and other subscribers twice per month, available in print
and online at bloodjournal.

American Society of Hematology
hematology

Fortifying cereals with a different type of iron supplement reduces anaemia, iron-deficiency
anaemia and general iron deficiency children in developing countries, and boosts three major
iron status indicators, conclude authors of an Article published in this week’s edition of
The Lancet.

Sodium Iron EDTA (NaFeEDTA) was found to be much more effective than electrolytic iron,
despite the electrolytic form being the most frequently used iron supplement in flour.

Pauline Andang’o, Kenya Medical Research Institute, Centre for Public Health Research,
Nairobi, Kenya and Netherlands-based colleagues studied 516 children aged three to eight
years from four schools in Marafa, Kenya, some 10% of whom were suffering from anaemia.

Anaemia is defined as a shortage of red blood cells and/or haemoglobin (the oxygen-carrying
iron complex) in the blood – one cause of which is iron deficiency.

The authors say: “Fortification of staple cereal flours could be a cost-effective, sustainable
way to improve iron status in developing countries.”

The children in the study were divided into four groups and each given the same amount
of porridge daily, five times a week. The placebo group had porridge made with unfortified
whole maize flour. For the other three groups the porridge was fortified with either high-dose
NaFeEDTA (56 mg/kg), low-dose NaFeEDTA (28 mg/kg) or electrolytic iron (56 mg/kg).

The researchers found that, compared to the placebo group, the prevalence of iron-deficiency
anaemia dropped by 89% for the high-dose NaFeEDTA group, and by 48% for the low-dose
NaFeEDTA group, but there was no evidence for any reduction in the electrolytic iron group.

High-dose NaFeEDTA fortified flour also improved three major iron status indicators in the
children taking flour fortified with it – haemoglobin and plasma ferritin concentrations,
and amounts of plasma soluble transferrin receptor. Low-dose NaFeEDTA also improved
these iron status indicators but to a lesser extent. Electrolytic iron had little effect on these
indicators.

Iron can bind to substances that occur naturally in cereals, which in turn prevents the iron
being absorbed in the intestines. But the EDTA molecule works by preventing the iron
and cereal binding, thus allowing the iron to be absorbed. The authors caution that more work must be done to determine the safe dosage of EDTA – which can in theory induce zinc
deficiency, although there is some evidence it can actually improve the absorption of dietary
zinc.

The authors conclude: “With continuous iron interventions, iron stores increase rapidly
and after two to three years reach plateau values that depend on the absorbable iron that is
supplied. Thus we think that continued intervention beyond five months would eventually
have led to an even greater discrepancy between the treatment effects associated with
NaFeEDTA and electrolytic iron.

“Consumption of whole maize flour fortified with high-dose NaFeEDTA reduced iron
deficiency anaemia, iron deficiency, and anaemia in Kenyan children.”

In an accompanying Comment, Dr Ted Greiner, a senior nutritionist from the international
non-profit health organisation PATH, Washington DC, USA, says: “Governments that
mandate fortification will, if they develop capacity for assessment and monitoring, be able to
ensure that the right nutrients are added to and maintained in key foods. Food fortification is
one of the most sustainable and cost-effective methods available to improve public health.

“These findings turn the tide: it is time to fortify the world’s processed cereals.”

lancet

Newborn Screening is an invaluable public health program that saves lives and helps to prevent the development of serious disease and debilitation. But how can privacy and autonomy best be maintained regarding the residual dried blood spots which are collected from newborns shortly after birth? To address this and other compelling issues surrounding the use of newborn screening blood spots, experts from across the US from a number of renowned institutions including the Mayo Clinic, the March of Dimes, the American College of Medical Genetics and the Genetic Alliance will host a public/professional forum and Internet webinar on “Blood Spots, Genetic Research and Privacy.”

Sponsored by the American College of Medical Genetics, the American College of Medical Genetics Foundation and the Genetic Alliance, this session is free and appropriate for the public, parents, health professionals, policymakers, the media and anyone with an interest in newborn screening.

The Forum will be held at the Bethesda North Marriott Hotel and Convention Center on Wednesday, September 23 from 7:00 – 9:00 pm and is free. Pre-registration is REQUIRED. The session will also be broadcast over the Internet as a free webinar. Visit https://www2.gotomeeting/register/989705827 to register for the free webinar.

The topics and speakers include:

Welcome: Michael S. Watson, PhD, FACMG, Executive Director, American College of Medical Genetics

Blood Spots, Genetic Research, and Privacy: Moderator – Sharon Terry, MA, President and CEO, The Genetic Alliance

Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy: Alan R. Fleischman, MD, Senior Vice President and Medical Director, The March of Dimes

The Public’s Perceptions Related to Uses of Newborn Screening Dried Blood Spots: Sharon Kardia, PhD, Professor and Chair, Dept. of Epidemiology, University of Michigan School of Public Health

The Many Lives of the Newborn Screening Dried Blood Spot: Piero Rinaldo, MD, PhD, FACMG, Professor of Laboratory Medicine, T. Denny Stanford Professor of Pediatrics, Mayo College of Medicine

Newborn Screening and its Improvement: A Consumer Perspective: Jana Monaco, Parent

Summary and Questions and Answers: Sharon Terry, MA, The Genetic Alliance

Source:
Kathy Ridgely Beal

American College of Medical Genetics

Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), a leading acute care therapeutics company, announced today that it has begun dosing in the CONSERV™-1 clinical trial with ecallantide. CONSERV™-1 is a Phase 2 trial evaluating the safety, efficacy, and clinical outcomes of various doses of ecallantide for the reduction of blood loss volume during on-pump cardiothoracic surgery. The trial is expected to enroll more than 300 patients undergoing on-pump cardiothoracic surgery.

Ecallantide is a potent inhibitor of plasma kallikrein, and CONSERV™-1 will evaluate the effects of plasma kallikrein inhibition in patients on cardiopulmonary bypass during cardiothoracic surgery. Such surgical environments are associated with the activation of plasma kallikrein and subsequent activation of coagulation, fibrinolytic, and inflammatory cascades, which likely contribute to blood loss and blood transfusion requirements in the perioperative setting.

“This trial represents an important event in the continued evaluation of ecallantide for the reduction of blood loss during on-pump cardiothoracic surgery, an area of significant unmet medical need and marked by the absence of any approved therapeutic options in the U.S. We anticipate that the results of this trial will provide meaningful insights into the optimal design of subsequent Phase 3 trials,” said Santosh Vetticaden, PhD, MD, Senior Vice President, Clinical Development and Chief Medical Officer.

“CONSERV™-1 demonstrates our continued commitment to the development of acute care therapeutics in areas of high unmet medical need,” said Steve Gilman, PhD, Senior Vice President, Discovery and Nonclinical Development and Chief Scientific Officer.

In April 2008, Cubist announced an exclusive North America and Europe license and collaboration agreement with Dyax Corp. (NASDAQ: DYAX) for the development and commercialization of the intravenous formulation of ecallantide for surgical indications. The first indication being sought by Cubist for ecallantide is the reduction of blood loss during on-pump cardiothoracic surgery.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM® I.V. (meropenem for injection) in the United States. MERREM is an established broad spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials – CONSERV-1 and the planned CONSERV-2 – for the reduction of blood loss during cardiothoracic surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam’s RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist’s web site at cubist.

Cubist Safe Harbor Statement

This press release contains forward-looking statements regarding the development of ecallantide for the reduction of blood loss volume during on-pump cardiothoracic surgery. There are many factors that could cause actual results to differ materially from those in these forward-looking statements. These factors include the following: (i) ecallantide may not show sufficient therapeutic effect or an acceptable safety profile in clinical trials; (ii) clinical trials of ecallantide may not be successful or conducted in a timely manner; (iii) the commercial market for the use of ecallantide for the reduction of blood loss volume during on-pump cardiothoracic surgery may not be as large as Cubist anticipates; (iv) others may develop technologies or products superior to ecallantide to treat blood loss during on-pump cardiothoracic surgery; (v) technical difficulties or excessive costs relating to the manufacture of ecallantide; (vi) Cubist or Dyax Corp., from which Cubist licensed its rights to ecallantide, may not be able to maintain and enforce the intellectual property protecting ecallantide; and (vii) other unanticipated or unexpected risks that may be encountered with respect to the development or manufacture of ecallantide. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cubist’s recent filings with the Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in such filings. These statements speak only as of the date of this release, and Cubist undertakes no obligation to update or revise these statements, except as may be required by law.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.

Source
Cubist Pharmaceuticals, Inc.

View drug information on Merrem I.V..

Biologists at the University of California, San Diego have discovered that the skin of mice can sense low levels of oxygen and regulate the production of erythropoietin, or EPO, the hormone that stimulates our bodies to produce red blood cells and allows us to adapt to high-altitude, low-oxygen environments.

Their surprising finding, published in the April 18th issue of the journal Cell, contradicts the notion of mammalian skin as an envelope around our bodies with little connection to the respiratory system.

If found to apply to humans, the discovery could radically change the way physicians treat anemia and other diseases that require boosting our bodies’ ability to produce red blood cells. It also could be used to improve the performance of endurance athletes competing in this summer’s Olympic Games.

“What we found in this study is really something quite unusual,” said Randall Johnson, a professor of biology at UC San Diego who headed the research study. “We discovered that mammalian skin, at least in mice, responds to how much oxygen is above it and, by virtue of that response, changes blood flow through the skin. This, in turn, changes one of the most basic responses to low oxygen that we have, which is the production of erythropoietin.”

Those responses, the researchers suspect, could be ancient traits retained as mammals evolved from lower forms of vertebrates, such as amphibians, that possess the same sorts of ion channels to promote oxygen diffusion in their extremely permeable skins as mammals have in their lungs.

“Amphibians – frogs most notably – breathe through their skin and are able to sense and respond to how much oxygen is in the air or water around their skin,” Johnson added. “But nobody had ever thought about asking those questions about the skin of mammals.”

“From an evolutionary point of view, the results make sense, considering the important role of the skin for oxygen uptake in amphibians,” said Frank Powell, a professor of medicine at UCSD and expert in human and animal adaptations to high-altitude environments who was part of the team. “It will be very interesting to see how these mechanisms work in humans and if, for example, different oxygen levels at the skin could affect how rapidly and how well one adapts to low oxygen in the intensive care unit of a hospital or at high altitude.”

The UC San Diego team found no evidence that mice could breathe through their skin. But if their discovery that mice sense low oxygen through their skin and trigger EPO production is found to apply to humans, it would have dramatic implications for the training and testing of endurance athletes during the Summer Olympic Games in Beijing.

Besides training at altitude and in low-oxygen tents – the two generally accepted legal methods of boosting red blood cell production – runners, swimmers, cyclists and other endurance athletes seeking better performances by increasing the oxygen-carrying capacity of their blood may now have another legitimate way to increase their red blood counts. Blood doping, the injection of additional red blood cells into the body, and the injection of synthetic recombinant EPO to boost red blood cell production are illegal in the Olympics and banned by most sports governing bodies. But what if athletes could boost their own EPO and red blood cell counts by exposing their bodies to low levels of oxygen” Or, to obtain the same effect, by merely increasing blood flow through their skin”

“We’ve discovered a potent physiological trigger that can be enacted or enabled without exogenous sources of EPO,” said Johnson. “We show in this paper that breathing in one level of oxygen and exposing your body to another level of oxygen is really a potent trigger for the body to produce its own EPO. It’s not hard to foresee people taking what we’ve learned in mice and applying it to humans.”

If human skin is found to be sensitive to oxygen levels, it could revive the debate over the “Goldfinger Syndrome.” This idea, perpetuated by the famous James Bond movie in which the villain’s girlfriend is killed after being painted gold, has been the focus of urban legends and internet discussions about the possible negative health effects of painting the skin. It has been the subject of two investigations by the Discovery Channel show “MythBusters.”

The team’s discovery – aided by collaborators in Sweden, Germany and the University of Pennsylvania – came after two years of trying to determine why certain mice the researchers had genetically engineered for experiments exhibited high levels of EPO. In 2004, Johnson and his students published a paper in the journal Plos Biology, detailing how they had transformed ordinary laboratory mice into the rodent equivalent of Olympic endurance athletes. They did this by deleting a gene that allows mammalian muscles to switch from aerobic to anaerobic metabolism when oxygen levels in the muscle run low.

Most of our daily activities are performed aerobically, through biochemical mechanisms in our muscles that make full use of oxygen. But when the demands of our muscular system exceed its available supply of oxygen, as in sprinting for a bus or lifting a heavy object, a protein known as hypoxia inducible transcription factor-1, or HIF-1, is activated. This protein enables the muscle to switch to the more energetically explosive, but expensive anaerobic process, which does not use oxygen and generates lactic acid as its byproduct.

When Johnson and students knocked out the negative regulator of the HIF-1 gene, they produced tiny mice with skin that look red and flushed. These mice have trouble retaining body heat because a larger proportion of their blood is sent to their skin and cooled, much like a person sitting in a hot sauna or Jacuzzi. But the most puzzling aspect of these mutant mice is their extremely high EPO levels – so high that 90 percent of their blood plasma is composed of red blood cells, compared to 40 to 50 percent for normal individuals.

“Their blood is basically paste and their hearts are enlarged as a result,” Johnson said. “We could not understand why the skin was exerting this effect. It just didn’t make sense to us. We could figure out every other aspect of why this mutant mouse looked an acted the way it did, but this one thing was really bothersome to us, so that sent us down this road. When we found that the EPO was coming from internal organs, not the skin of these mice, we thought there must be some kind of signal from the skin to the internal organs.”

Johnson and others in his laboratory – graduate student Adam Boutin, postdoctoral fellow Alexander Weidemann and undergraduate Lernik Mesropian – verified that the HIF-1 gene was responsible by genetically engineering mutant mice without the gene in their skin cells. These mice were unable to signal the production of extra EPO when their skin was exposed a chamber filled with 10 percent oxygen – about the level found at Mount Everest. The concentration of oxygen at sea level is about 21 percent. Normal mice were able to increase the amount of EPO production at this 10 percent level.

This occurred, the researchers found, when more blood rushed into the skin. By putting on the mouse’s skin a nitroglycerine patch, which increases blood flow through the skin, the researchers found that mice could dramatically increase their production of EPO and red blood cells.

“EPO administration is a multi-billion dollar drug market for the treatment of all sorts of diseases involving low red blood cell counts,” said Johnson. “So the ability to manipulate red blood cell production just by changing blood flow through certain parts of the skin could be profound. We show in this study that by just putting a little nitroglycerine patch we were able to trigger very big increases in EPO. Whether this turns out to be true for humans, we don’t know yet. But potentially this could be a very interesting way to manipulate this pathway.”

Johnson and his team, which included UCSD assistant professor of biology Colin Jamora, found that having mice breathe in a chamber with their entire bodies exposed to low levels of oxygen had the greatest response and produced the most EPO. When the mice were allowed to breathe 10 percent oxygen in one chamber, but had the skin from their neck down exposed to 21 percent, or sea-level oxygen, in another chamber built by Powell, more than one-half of their adaptation to low oxygen was lost.

“If we put mice that lack a hypoxic response in their skin in a low oxygen chamber more than half of their hypoxic response goes away and that was surprising to us,” Johnson said. “The skin really is a big contributor to the way the mouse responds to low oxygen.”

“All of the important responses to hypoxia, or low oxygen, were thought to be triggered by oxygen-sensitive nerves and molecules in the blood and internal organs,” said Powell. “However, these experiments clearly show that the skin directly responds to changes in oxygen in the environment with changes in blood flow. These changes in skin blood flow are highly significant by causing changes in the levels of hypoxic inducible factor, which is a sort of ‘master switch’ for adapting to low oxygen that activates multiple genes to enhance oxygen delivery throughout the body.”

Johnson said that because people with skin inflammations such as psoriasis and eczema can have low red blood cell counts, he and his team are interested in extending their study to investigate anemia caused by skin inflammations in their mutant mice.

“In people with anemia of inflammation it seems as if the EPO isn’t having an effect,” he added. “We actually have mutant mice with skin inflammation that show this same effect. They have high EPO levels, but they don’t have a high red blood cell count. The mutants we used in our study have high EPO levels and high red blood cell counts. But they don’t have inflammation. The next step for us is going to be trying to figure out why these inflammatory diseases trigger EPO. Is there something about inflammation that we can trigger so these people can be treated without suffering this kind of anemia””

The scientists said in their paper that their discovery also might explain why people in some parts of Nepal, India and Pakistan massage newborn babies in mustard oil, a mild irritant that promotes blood flow through the skin.

“We show in this study that if you paint the skin of a mouse with this mild irritant, mustard oil, it will also trigger EPO release at a somewhat lower level,” Johnson said. “In India and Pakistan babies are in some communities massaged in mustard oil at birth; and some health workers have been trying to get them to stop this folk tradition. But we show that in mice this increases EPO levels. And since increased EPO levels contribute to increased red blood cell counts one could imagine it being beneficial.”

The study was funded by grants from the National Institutes of Health, the Wenner-Gren Foundation and the Swedish Foundation for International Cooperation in Research and Higher Education.

Source: Kim McDonald

University of California – San Diego

Research on blood transfusions points to a potential risk of transfusing donated platelets, especially to patients with bone marrow failure syndromes who are subsequently candidates for bone marrow transplantation.

The results are online and scheduled for publication in the September 1 issue of the Journal of Clinical Investigation.

Doctors have noticed a pattern in performing bone marrow transplants as a cure for diseases involving bone marrow failure: more transfusions before a bone marrow transplant correlates with a higher likelihood of rejection, says James Zimring, MD, PhD, assistant professor of pathology and laboratory medicine at Emory University School of Medicine.

However, the cause-and-effect relationship between transfusion and bone marrow transplant rejection is unclear. More transfusions may just be needed to treat more severe disease, and more severe underlying disease may cause increased rates of bone marrow transplant rejection, Zimring says.

“Platelets are mostly given to prevent or to stop acute bleeding or hemorrhage. Clearly, none of us would risk a patient bleeding to avoid possible complications for a subsequent bone marrow transplant. Greater understanding of the biology involved is required to modify our transfusion and/or transplantation procedures so as to circumvent the problem,” he says.

Bone marrow failure syndromes can be inherited or acquired as result of infection or exposure to radiation, insecticides or industrial solvents. Bone marrow failure means the bone marrow can’t produce new blood cells, leading to anemia, trouble fighting infections and difficulty controlling bleeding.

To probe for the causes of bone marrow transplant rejection after transfusions, Zimring, graduate student Seema Patel and co-workers established a model system in mice. The system was designed to simulate transplants for bone marrow failure syndromes and do not apply to transplants carried out to treat cancer, which destroy more of the immune system beforehand.

They found that platelet transfusions given to mice before a bone marrow transplant drastically increased the likelihood that the transplant will be rejected.

Donor and recipient were “matched” for their MHC (major histocompatibility complex) genes, the most important determinants of transplant compatibility.

Platelets are already processed to remove white blood cells, with the aim of reducing the risk of immune-related problems. In addition, blood banks already test for antibodies against proteins encoded by MHC genes. In humans, MHC genes are known as HLA (human leukocyte antigen).

Zimring says the remaining concern about immune incompatibility comes from other proteins on the platelets themselves, termed “minor antigens.” Immune responses to minor antigens are not currently monitored in patients, so the extent to which they occur is unknown.

Ultimately, modification of the transfused platelets or matching for minor antigens on donated platelets may remedy the problem, he says. A careful human clinical study would be required to establish if the same mechanisms occur in humans.

A related paper by Zimring and his colleagues describing the effects of pre-transplant transfusions of red blood cells in mice was recently published in the journal Blood.

Notes:
The research was supported by the National Institutes of Health.


References: S.R. Patel, C.M. Cadwell, A. Medford and J.C. Zimring. “Bone Marrow Transplant Rejection Induced by Platelet Transfusion.” J. Clin. Invest. 119: (Sept 2009).

M. Desmarets, C.M. Cadwell, K.R. Peterson, R. Neades, and J.C. Zimring. “Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model.” Blood (epub before print).

Source:
Holly Korschun

Emory University

Speaking at the Venous Disease Coalition (VDC) Annual Meeting today, Dr. Garth Graham from the Office of Minority Health at the Department of Health and Human Services followed up on last year’s Surgeon General’s Call to Action by focusing attention on the African American population which is at significantly increased risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

African Americans have a significantly higher risk of developing potentially deadly DVT and PE compared with other ethnic populations in the U.S., according to data presented by Dr. Graham.

“One person dies every five to six minutes from a DVT or PE related event in America, and some groups such as African Americans are at a significantly higher risk of developing these conditions,” said Dr. Graham, who lost his sister to PE. “Many of the causes of DVT are entirely preventable and easily treatable, so it’s crucial that people understand their level of risk and take action to reduce this. Improved awareness and access to treatment can save a great number of lives.”

To help raise awareness, the VDC has launched the “Pause for Prevention” DVT and PE Assessment, a tool to help people better understand if they are at risk for DVT or PE. This is available on venousdiseasecoalition.

“I suffered from DVT just over six years ago when I was in my mid-twenties, and the experience was daunting. Not necessarily because of the clots per se, those were treatable, but because it took several trips to doctors and the ER before I had an accurate diagnosis and started to receive appropriate treatment,” comments Traci Wilkes Smith. “I am reaching out to others to let them know to ask more questions and be more aggressive if you suspect something is wrong. Know the signs and be an informed patient, it could save your life.”

Approximately 350,000 to 600,000 Americans suffer from DVT and PE each year, and at least 100,000 deaths may be directly or indirectly related to these diseases. African Americans have a remarkable 30 percent higher risk of DVT and PE than the Caucasian population.1

According to Samuel Z. Goldhaber, MD, president of the Venous Disease Coalition and professor of medicine at Harvard Medical School, “With prompt diagnosis and treatment, the majority of DVTs are not life threatening. We can help reduce deaths from these serious yet often preventable conditions through education and outreach to at-risk groups including African Americans.”

About DVT

DVT occurs when a blood clot develops in the large veins of the legs or pelvic area. With prompt diagnosis and treatment, the majority of DVTs are not life threatening. However, DVT can be dangerous in two ways. First, DVT can be fatal if a blood clot breaks free and travels through the heart and into the lungs. This complication is called pulmonary embolism (PE). Second, because blood clots can
permanently damage the veins, as many as half of DVT survivors can experience post-thrombotic syndrome which causes long-term leg pain, heaviness and swelling that can progress to difficulty walking, changes in skin color and open leg sores.

Risk factors for developing DVT / PE include extended bed rest (such as during or after a surgical procedure or illness (such as heart attack or stroke), or confinement and inability to walk (such as during prolonged air or car travel), hereditary factors, medical conditions (such as congestive heart failure, severe obesity, chronic respiratory failure), a history of smoking, varicose veins, pregnancy and estrogen treatment, and some cancers or cancer treatments that predispose the blood to clotting. Reasons why African Americas are at increased risk for DVT and PE remain to be determined. To view a short video clip of Dr. Graham speaking about the increased risks for DVT and PE in African Americans visit,
here.

At last year’s VDC meeting, Acting Surgeon General Rear Admiral Steven K. Galson issued “The Surgeon General’s Call to Action for the Prevention of Deep Vein Thrombosis and Pulmonary Embolism.”

About Dr. Garth Graham

Dr. Garth N. Graham is the Deputy Assistant Secretary for Minority Health and Director of the Office of Minority Health at the Department of Health and Human Services. He was previously appointed a White House Fellow and special assistant the Secretary of Health and Human Services. He founded the Boston Men’s Cardiovascular Health Project, a project designed to identify behavioral explanations for decreased adherence to adequate diet and exercise by African American men. He is currently on the faculty of Harvard Medical School and serves as a visiting scientist at the Harvard School of Public Health. He has authored scientific articles and presentations on cardiovascular disease, HIV/AIDS and community medicine.

About the Venous Disease Coalition

The Venous Disease Coalition (VDC) is an alliance of more than 35 leading health professional societies and patient advocacy groups that have united around a common goal: To improve the survival rates and quality of life for individuals with, or at risk for, venous disease. The VDC plans to develop a national campaign to educate public and health care professionals in the U.S. about venous disease. The VDC is supported by unrestricted educational grants from AngioDynamics Inc., BioMedix, BSN Jobst, Cook Medical, Covidien, Eisai Inc., Juzo and Sanofi-aventis. It is a program of the Vascular Disease Foundation. For more information, visit VenousDiseaseCoalition.

References

1 White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005;93(2):298-305.

Source
Vascular Disease Foundation

Kimball Genetics, Inc. is pleased to
announce today the launch of its Warfarin Sensitivity DNA Test for
research/investigational purposes. Warfarin is the most frequently
prescribed oral anticoagulant used for the prevention and treatment of
thromboembolic events. However, it is a difficult drug to manage due to its
narrow therapeutic range and inconsistent patient response resulting from
inter-individual variability. Genetic information available from the new
pharmacogenomic test will help predict response. The Warfarin Sensitivity
DNA Test determines the presence of specific variations in the CYP2C9 and
VKORC1 genes that confer sensitivity to warfarin and thus significantly
reduce the required maintenance dose. CYP2C9 is involved in warfarin
metabolism and VKORC1 influences warfarin’s anticoagulation effect through
vitamin K. Kimball Genetics expects to offer the Warfarin Sensitivity DNA
Test for routine clinical use early in 2007.

The FDA Clinical Pharmacology Subcommittee of the Advisory Committee
for Pharmaceutical Sciences has recommended testing for variations in the
CYP2C9 and VKORC1 in patients requiring warfarin therapy. The drug label
will reflect this recommendation soon.

The Warfarin Sensitivity DNA Test that Kimball offers informs the
prescriber about the presence of genetic risk factors for
overanticoagulation and should help achieve the correct maintenance dose
faster. It is also likely to increase the safety and efficacy of warfarin
treatment. The DNA test identifies patients who are sensitive to warfarin
and who therefore: 1) require a lower dose to achieve a target INR, 2) may
be at an increased risk for bleeding complications, and 3) without the DNA
test, would require a longer period of time to achieve stable warfarin
dosing.

Kimball Genetics welcomes research and clinical trial collaborations
and with academic institutions, pharmaceutical companies, and other
companies requiring genotype information for studies involving warfarin.
One such project currently underway is “Pharmacogenetics for Coumadin” with
pathologist Dr. David Feldman of the St Luke’s Episcopal Hospital in
Houston, TX.

“We are excited to be expanding into the pharmocogenomic arena with the
Warfarin Sensitivity DNA Test,” says Dr. Annette K. Taylor, President and
CEO of Kimball Genetics, Inc. “With our one day turnaround time we believe
we will be able to offer physicians the quick answers they need regarding
their patients’ sensitivity to warfarin and their dosing requirements.”
Kimball Genetics is committed to the growing application of pharmacogenomic
testing to mainstream medicine and plans to offer more tests in 2007 and
beyond. “This is the beginning of a new era of personalized medicine which
will allow individual customization of drug therapy,” remarks Dr. Taylor.
Kimball Genetics is a member of the Personalized Medicine Coalition, a
non-profit group of academic and industrial organizations, patient groups,
and healthcare providers dedicated to advancing the adoption of
personalized medicine for the benefit of patients.

About Kimball Genetics, Inc.

Founded in 1994 by Annette K. Taylor, M.S., Ph.D., Kimball Genetics is
a national DNA diagnostic laboratory located in Denver, CO and specializing
in testing for common genetic disorders that are preventable or can be
treated. Known for its unparalleled turnaround time and distinctive focus
on genetic counseling and education, the company’s major areas of testing
currently include inherited hypercoagulability, celiac disease,
hemochromatosis, cystic fibrosis, and fragile X syndrome. The Warfarin
Sensitivity DNA Test is Kimball’s first offering in an exciting new
pharmacogenomics program.

Kimball Genetics, Inc.
kimballgenetics

View drug information on Warfarin Sodium tablets.

Tag Cloud